| Literature DB >> 35877434 |
Josué Manríquez-Núñez1, Minerva Ramos-Gómez1.
Abstract
Overweight and obesity have become worldwide health issues in most countries. Current strategies aimed to prevent or reduce overweight and obesity have mainly focused on the genes and molecular mechanisms that give the functional characteristics to different types of adipose tissue. The Browning phenomenon in adipocytes consists of phenotypic and metabolic changes within white adipose tissue (WAT) activated by thermogenic mechanisms similar to that occurring in brown adipose tissue (BAT); this phenomenon has assumed great relevance due to its therapeutic potential against overweight and obesity. In addition, the study of inflammation in the development of overweight and obesity has also been included as a relevant factor, such as the pro-inflammatory mechanisms promoted by M1-type macrophages in adipose tissue. Studies carried out in this area are mainly performed by using the 3T3-L1 pre-adipocyte cell line, testing different bioactive compound sources such as plants and foods; nevertheless, it is necessary to standardize protocols used in vitro as well to properly scale them to animal models and clinical tests in order to have a better understanding of the mechanisms involved in overweight and obesity.Entities:
Keywords: 3T3-L1 cell line; adipocyte browning; bioactive compounds
Year: 2022 PMID: 35877434 PMCID: PMC9320013 DOI: 10.3390/cimb44070210
Source DB: PubMed Journal: Curr Issues Mol Biol ISSN: 1467-3037 Impact factor: 2.976
Characteristics and differences among white (WAT), brown (TAB) and beige (BeAT) adipose tissues.
| WAT | BAT | BeAT | Authors | |
|---|---|---|---|---|
| Anatomical location | Subcutaneous and visceral | Adrenal, interscapular, and neck area in human infants | WAT deposits and supraclavicular region | [ |
| Morphology | Large adipocytes | Small adipocytes | Small adipocytes | [ |
| Lipid droplets | Large | Multiple and small | Multiple and small | [ |
| Origin/development | Progenitor Pdgfr-α | Progenitor Myf5+ | Progenitor Pdgfr-α+ | [ |
| Primary function | Energy storing | Heat production | Heat production | [ |
| Endocrine signals/adopokines | Adiponectin, Adipsin, Omentin, IL-4, IL-6, IL-10, Leptine, Resistin, Visfatin, Chemerin, TNF-α, MCP-1 | FGF-21, NRG-4, Myostatin, IGF-1, CXCL-14, BMP-8b, VEGF-A, T3, IL-6, GDF-15, Adiponectin, S100b, NGF and EPDR1 | IGFBP-2, METRNL, IL-6, GDF-15 and SLIT2-C | [ |
| Mitochondrial UCP1 | Low/high upon | Low/high upon stimulation | Low/high upon | [ |
| Expressed genes | Asc1, Fabp4, Fbxo31, Leptin, Lpl, Mpzl2, Nr1H3, Nrip1, Rb1, Rbl1, Resis-tin, Serpina3K, Tcf21 and Wdnm1 | Bmp7, Efb2, Ednrb, Eva1, Mir133B, Mir206, Myf5, Pdk4, Prex1 and Zic1 | Aqp7, Asc1, Car4, Cd137, Cd40, Cited1, Ear2, Shox2, Slc27A1, Sp100, Tbx1 and Tmem26 | [ |
| Mitochondrial biogenesis | Low | High | Medium | [ |
| Activated hyperplasia or hypertrophy | In prolonged positive energy balance conditions, adipocytes expand cell size (hypertrophy) and number (hyperplasia). | An increase in thermogenic activity derived from physical activity has been reported; however, it has not been related to tissue expansion. | Not reported | [ |
| Insulin resistance | Led by sustained low-grade inflammatory process. | Negative | Negative | [ |
In-vitro effects of several bioactive compounds on the browning phenomenon.
| Compound/Extract | Concentration Range Evaluated | Results | Authors |
|---|---|---|---|
| Compound K (bacterial gingenoside) | 5 μM | Inhibits adipocyte maturation from pre-adipocyte to white adipocyte, decreases adipogenesis and lipid accumulation. | [ |
| Ginsenoside Rb1 | 0.01, 0.1, 1, 10 and 100 μM | Improves glucose intake and induction of thermogenic genes involved in browning process. | [ |
| Albiflorin | 10 and 20 µ | Decreases lipid accumulation and reduces adipogenic-related gene expression | [ |
| Farmesol | 0.5 and 2 µM | Decreases lipid accumulation and adipogenic-related genes, and induces thermogenic activity | [ |
| β-Lapachone | 0.5, 1 and 2 µM | Decreases lipid accumulation and induces thermogenic genes involved in browning process. | [ |
| Caffeine | 1 µM | Increases oxygen consumption and thermogenic genes. | [ |
| Ginsenoside Rg3 | 20 and 40 µM | Induction of thermogenic genes in mature differentiated white adipocytes. | [ |
| Magnolol | 1, 5, 10 and 20 µM | Induction of thermogenic genes involved in browning process during pre-adipocyte maturation process. | [ |
| δ-Tocopherol | 10, 50 and 100 μM | Induction of thermogenic genes involved in browning process in mature differentiated white adipocytes. | [ |
| Thymol | 20 μM | Promotes mitochondrial biogenesis and increases lipid oxidation. | [ |
| Trans-anethole | 1, 10, 50 and 100 μM | Decreases adipogenesis and lipogenesis during pre-adipocyte maturation process | [ |
| Cyanidin-3-glucoside | 50 and 100 µM | Increases multilocular lipid droplets and mitochondrial biogenesis. | [ |
| Gallotannins | 2.5, 5, 10 and 20 mg/mL | Induction of thermogenic genes involved in browning process in pre-adipocytes and during pre-adipocyte maturation process. | [ |
| Resveratrol | 10, 20 and 40 µM | Induction of thermogenic genes and decrease in lipid accumulation in mature differentiated white adipocytes. | [ |
| Lycopene | 1, 2, 4 and 10 μM | Induction of thermogenic genes and decrease the lipid accumulation. | [ |
| Grape pomace | 30 µM | Increases the β-adrenergic pathway and mitochondrial biogenesis. | [ |
| Raspberry ketone | 50 and 100 µM | Induction of thermogenic genes and mitochondrial biogenesis. | [ |
| Strawberry extract ( | 0, 10, 50 and 100 µg/mL | Inhibits adipocyte maturation from pre-adipocyte to white adipocyte. | [ |
Composition of differentiation media and maturation period of different studies related to adipocyte browning performed on the 3T3-L1 and hAMSc cell lines.
|
|
|
|
|
| |
| Compound K (bacterial gingenoside) | DMEM, 10% FBS, 1% streptomycin-penicillin, 1 μg/mL Ins, 1 μM DEX, and 0.5 mM IBMX. | 8 days | 48 h after confluence. | [ | |
| Ginsenoside Rb1 | DMEM, 10% FBS, 0.1% Gentamicin, 0.05% Biotin, 1 μM Ins, 0.25 μM DEX, and 0.25 mM IBMX. | 7 up to 9 days | 1 h after differentiation period under starving conditions. | [ | |
| Cyanidin-3-glucoside | DMEM, 10% FBS, 1% streptomycin-penicillin, Ins, DEX and IBMX. | 7 days | During differentiation period. | [ | |
| Magnolol | DMEM, 10% FBS, 1% estreptomicina-penicilina, 10 μg/mL Ins, 0.25 μM DEX y 0.5 mM IBMX. | Not detailed | During differentiation period. | [ | |
| Quercetin | DMEM, 10% FBS, 1% streptomycin-penicillin, 1 μg/mL Ins, 0.25 mM DEX and 0.5 mM IBMX. | 11 days | During differentiation period (day 5 to 11). | [ | |
| Thymol | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 0.25 μM DEX and 0.5 mM IBMX. | 6 up to 8 days | During differentiation period. | [ | |
| Gallotannins | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 1 μM DEX and 0.5 mM IBMX. | 6 days | 48 h after differentiation period. | [ | |
| Grape pomace | DMEM, 10% FBS, 1% streptomycin-penicillin, 1 mM/L Ins, 0.25 mM/L DEX, 0.5 mM/L IBMX, and 0.1 mM/L indomethacin. | 10 days | 20 min after differentiation period. | [ | |
| Raspberry ketone | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 0.25 μM DEX, and 0.5 mM IBMX. | 10 days | During differentiation period (day 6 to 8) | [ | |
| δ-Tocopherol | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 2.5 μM DEX and 0.5 mM IBMX. | 10 days | During differentiation period. | [ | |
| Trans anethole | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 0.25 μM DEX and 0.5 mM IBMX. | 6 up to 8 days | During differentiation period. | [ | |
| Ginsenoside Rg3 | DMEM, 10% FBS, 1% streptomycin-penicillin, 5 μg/mL Ins, 1 μM DEX and 0.5 mM IBMX. | Not detailed | 24 h after differentiation period. | [ | |
| Lycopene | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 1 μM DEX and 0.5 mM IBMX. | 6 up to 8 days | 24 and 48 h, respectively. | [ | |
| Resveratrol | DMEM, 10% FBS, 1% streptomycin-penicillin, 10 μg/mL Ins, 0.5 μM DEX and 0.5 mM IBMX. | 6 up to 8 days | During differentiation period. | [ | |
| Strawberry extract ( | DMEM, 10% FBS, 1% streptomycin-penicillin, 1 μg/mL Ins, 1 μM DEX, and 0.5 mM IBMX. | 10 days | During differentiation period. | [ | |
|
| |||||
|
|
|
|
|
|
|
| Albiflorin | hAMSCs | DMEM, 10% SFB, 1% streptomycin-penicillin, 1 μg/mL Ins, 1 μM DEX, 0.5 mM IBMX and 100 μM Indomethacin | 14 days | After maturation, not detailed | [ |
| Farnesol | hAMSCs | DMEM, 10% SFB, 100 U/mL streptomycin-penicillin, 1 μM Ins, 1 μM DEX, 0.5 mM IBMX and 100 μM Indomethaci | 15 days | During differentiation maturation (day 6 to 15) | [ |
| β-Lapachone | hAMSc | DMEM, 10% SFB, 100 U/mL streptomycin-penicillin, 1 μM Ins, 1 μM DEX, 0.5 mM IBMX and 100 μM Indomethacin | 14 days | Not detailed | [ |
| Caffeine | mMSCs/hMSCs | DMEM, 10% SFB, 100 U/mL strep-tomycin-penicillin, 10 μg/mL Ins, 1 μM DEX, 100 µM IBMX, 1 µM Rosiglitazone and 1 nM T3/DMEM, 10% SFB, 100 U/mL streptomycin-penicillin, 10 μg/mL Ins, 1 μM DEX, 500 µM IBMX, 1 µM Rosiglitazone and 1 nM T3 | Not detailed | 7 days | [ |
Research about thermogenic characteristics and molecular elements related to the phenomenon of browning in in-vivo models and clinical studies.
| Model | Compound | Molecular Target | Technique | Authors |
|---|---|---|---|---|
| Mouse | - | UCP-1 | Magnetic resonance detection | [ |
| Mouse | Norepinephrine and rosiglitazone | UCP-1 | Transgenic mouse for UCP-1 luciferase signal | [ |
| Mouse | Albiflorin | UCP-1, PGC-1α, Nrf1, LIPIN1 and Glut4 | qPCR and Western blot analyses | [ |
| Mouse | Farmesol | UCP-1 | qPCR and Western blot analyses | [ |
| Mouse | β-Lapachone | UCP-1, PGC-1α and CIDEA. | qPCR and Western blot analyses | [ |
| Human | Caffein | Supraclavicular region activity | Infrared thermography | [ |
| Human | Hydrocortisone | - | Infrared thermography | [ |
| Mouse | - | UCP-1 | UCP-1 fluorescent probe detected by ultrasonic tomography | [ |
| Rat | Grape pomace | PPARγ, MCP-1, PRDM16, PGC-1α | Primary adipocyte cell culture | [ |